Business Context and Reporting Period
Company: InnovAge Holding Corp. (INNV)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2026
Business Overview: InnovAge is the largest Program of All-Inclusive Care for the Elderly (PACE) provider in the U.S. by participant count. The company operates 20 PACE centers across six states (California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia), serving approximately 8,230 frail, dual-eligible seniors as of June 30, 2026. The company operates as a single reportable segment (PACE) and assumes 100% of the financial risk for participant healthcare costs under capitated contracts with Medicare and Medicaid.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 |
|---|---|---|
| Total Revenues | $989.7 million | $853.7 million |
| Operating Income (Loss) | $2.6 million | $(29.8) million |
| Net Loss | $(0.7) million | $(35.3) million |
| Net Loss Attributable to InnovAge | $(2.5) million | $(30.3) million |
| Adjusted EBITDA (Non-GAAP) | $94.6 million | $34.5 million |
| Center-Level Contribution Margin (Non-GAAP) | $227.8 million | $153.6 million |
| Cash and Cash Equivalents | $97.9 million | $64.1 million |
| Total Debt Outstanding | $48.8 million | $60.0 million |
| Revolving Credit Facility Capacity | $93.8 million available | N/A |
Material Changes Versus Prior Period
- Revenue Growth: Total revenues increased 15.9% year-over-year, driven by a 7.8% increase in member months and a 7.6% increase in capitation rates (including an 8.4% increase in Medicaid rates).
- Profitability Improvement: The company narrowed its net loss significantly from $35.3 million in 2025 to $0.7 million in 2026. Operating income turned positive ($2.6 million) compared to a loss of $29.8 million in the prior year.
- Expense Increases: Corporate, general, and administrative expenses rose 36.4% to $166.5 million, primarily due to a $36.8 million increase in litigation expenses and accruals related to civil investigative demands. Cost of care increased 16.1% due to higher wage rates and the transition to in-house pharmacy services.
- Debt Reduction: Total debt decreased by $11.2 million as the company made principal payments on its Term Loan A Facility.
- Impairments: Impairments and loss on assets held for sale decreased significantly from $13.6 million in 2025 to $3.2 million in 2026, reflecting the cessation of development for a planned center in Downey, California.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: Management expects to continue investing in growth, including de novo centers and acquisitions, while focusing on operational efficiency. The company anticipates a more constrained rate environment in fiscal 2027, particularly in Colorado where Medicaid premium rates are expected to decrease retroactively. The company is deploying AI-enabled tools to manage cost trends and reduce unwarranted variation in provider practice patterns.
Key Risks and Contingencies:
- Regulatory and Legal: The company is subject to ongoing civil investigative demands from the Department of Justice (DOJ) and state attorneys general under the False Claims Act. As of June 30, 2026, the company has accrued approximately $37.0 million for potential settlements and litigation costs. There is no assurance that settlements will be reached on expected terms.
- Legislative Impact: The "One Big Beautiful Bill Act" (Reconciliation Act) signed in July 2025 mandates significant reductions in federal Medicaid spending and introduces new eligibility redetermination requirements. This creates budgetary pressures that could lead to reduced capitation rates and enrollment delays.
- California Moratorium: Effective November 2025, the California Department of Health Care Services paused PACE applications for new centers for two years, constraining expansion in the company's largest market.
- Operational Risk: The company faces labor shortages and wage inflation, particularly in California due to new minimum wage laws for healthcare workers. Additionally, the transition to a new Medicare risk adjustment model (V28) may reduce risk scores and revenue growth.
Investor Verification Checklist
- Litigation Accruals: Verify the sufficiency of the $37.0 million accrual for DOJ and state False Claims Act investigations and the potential for additional material losses.
- Reconciliation Act Impact: Assess the specific financial impact of the Reconciliation Act on Medicaid reimbursement rates and eligibility redetermination processes in key states (California, Colorado).
- California Expansion: Confirm the status of the Bakersfield de novo center application and the impact of the two-year moratorium on new center openings in California.
- Pharmacy Integration: Evaluate the cost savings and operational performance of the in-house pharmacy services acquired from Tabula Rasa HealthCare Group.
- Debt Covenants: Review compliance with the Credit Agreement covenants, specifically the secured net leverage ratio, given the company's historical losses and current debt structure.